Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis.
- Author:
Juan-Yi FENG
1
;
Chuang-Qi WU
;
Peng ZHANG
;
She-Jiao WANG
;
Xiang-Hong ZHENG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Bone Neoplasms; drug therapy; secondary; Diphosphonates; therapeutic use; Humans; Imidazoles; therapeutic use; Male; Middle Aged; Neoplasm Metastasis; drug therapy; Organometallic Compounds; therapeutic use; Organophosphorus Compounds; therapeutic use; Prostatic Neoplasms; drug therapy; pathology
- From: National Journal of Andrology 2012;18(11):982-985
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the efficacy of 153Sm-EDTMP in the treatment of bone metastasis of prostate cancer (PCa) by comparison with zoledronic acid.
METHODSWe assigned 55 PCa patients with bone metastasis to receive 153Sm-EDTMP (n = 31) and zoledronic acid (n = 24), the former injected intravenously at the dose of 37.0 MBq/kg body weight, and the latter administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride. We performed 99mTc-MDP bone scan before and 1 -2 months after the treatment.
RESULTSThe rate of pain relief was 83.9% in the 153Sm-EDTMP group and 58.3% in the zoledronic acid group (P = 0.035), and that of bone metabolism change was 64.5% in the former and 33.3% in the latter (P = 0.022).
CONCLUSION153Sm-EDTMP is an ideal agent for the treatment of prostate cancer with bone metastasis.
